Nicastrin Interacts with γ-Secretase Complex Components via the N-terminal Part of Its Transmembrane Domain*

Received for publication, September 24, 2003, and in revised form, November 4, 2003
Published, JBC Papers in Press, November 5, 2003, DOI 10.1074/jbc.C300435200

Anja Capell, Christoph Kaether, Dieter Edbauer, Keiko Shirotani, Sabine Merkl, Harald Steiner, and Christian Haass†

From the Adolf-Butenandt-Institute, Department of Biochemistry, Laboratory for Alzheimer’s and Parkinson’s Disease Research, Schillerstrasse 44, Ludwig-Maximilians-University, 80336 Munich, Germany

Two secretases are involved in the generation of amyloid β-peptide, the principal component of amyloid plaques in the brains of Alzheimer’s disease patients. While β-secretase is a classical aspartyl protease, γ-secretase activity is associated with a high molecular weight complex. One of the complex components, which is critically required for γ-secretase activity is nicastrin (NCT). Here we investigate the assembly of NCT into the γ-secretase complex. NCT mutants either lacking the entire cytoplasmic tail, the cytoplasmic tail, and the transmembrane domain (TMD), or containing a set of heterologous TMDs were expressed in cells with strongly reduced levels of endogenous NCT. Maturation of exogenous NCT, γ-secretase complex formation and proteolytic function was then investigated. This revealed that the cytoplasmic tail of NCT is dispensable for γ-secretase complex assembly and function. In contrast, the authentic TMD of NCT is critically required for the interaction with γ-secretase complex components and for formation of an active γ-secretase complex. Neither soluble NCT lacking any membrane anchor nor NCT containing a heterologous TMD were inserted into the γ-secretase complex. We identified the N-terminal region of the NCT TMD as a functionally important entity of NCT. These data thus demonstrate that NCT interacts with other γ-secretase complex components via its TMD.

Secretases are protease activities known to be required for proteolytic processing of the β-amyloid precursor protein (βAPP). βAPP is the precursor for the neurotoxic amyloid β-peptide (Aβ), the principal component of amyloid plaques invariably found in all Alzheimer’s Disease (AD) brains (1, 2). Apparently the highly insoluble Aβ aggregates immediately after its proteolytic generation by secretases and forms oligomers, which are the main pathological players in the disease (3). Thus understanding secretase function is not only of great academic interest but will also help to develop therapeutic strategies against AD.

Two secretases are involved in Aβ generation. The first cut is mediated at the Met/Asp bond at amino acid one of the Aβ peptide by β-site APP cleaving enzyme. β-Site APP cleaving enzyme is a membrane-bound protease, which contains the classical active sites of aspartyl proteases (4). In contrast γ-secretase activity is associated with a high molecular weight protein complex (5–8). The first proteins identified within these complexes were the two homologous presenilins (PS1/PS2) (5, 9). PSs were originally found by their genetic linkage to early onset familial AD (10). PS mutations were shown to affect Aβ generation in a pathological manner by increasing the production of the 42 amino acid Aβ42, which tends to oligomerize much faster than the regular 40 amino acid Aβ40 (7, 8). PSs contain two conserved aspartyl residues, which are critically required for γ-secretase activity and their endoproteolysis (11). PSs must associate with a number of additional proteins to gain proteolytic activity (7, 8). Most likely all functionally essential components have now been identified (12). Besides PS1 and PS2 these include nicastrin (NCT), PEN-2, and APH-1a/APH-1b (12–14). These components are required and sufficient to reconstitute γ-secretase activity in yeast, an organism lacking any endogenous γ-secretase activity (15). Complex formation and generation of a proteolytically active γ-secretase complex is coordinate regulated and removing any one of the four components results in the lack of γ-secretase activity and expression or maturation of the remaining partners (12, 16–22). APH-1 and NCT are apparently required for the stabilization of full-length PS, whereas PEN-2 stimulates endoproteolysis of PS and/or stabilizes the resulting PS fragments (17, 20, 23). The complex glycosylation of NCT indicates transport to distal compartments (18, 22), and components of the γ-secretase complex have been detected at the plasma membrane (19, 24, 25). Although probably all components of the γ-secretase complex have now been identified, little is known about the individual interactions of components, their assembly into the complex, and trafficking of the complex to its sites of biological activity. To identify domains of NCT required for complex assembly we investigated NCT variants, which either lack the cytoplasmic tail, the complete transmembrane domain (TMD) and the cytoplasmic tail thus generating a soluble NCT variant, or containing a heterologous TMD. We demonstrate that NCT preferentially interacts via the N-terminal half of its TMD with other γ-secretase complex components and does not require the cytoplasmic domain.

EXPERIMENTAL PROCEDURES

Cell Culture and Cell Lines—Human embryonic kidney 293 cells (HEK 293) stably expressing swAPP and the NCT knockdown cell line
were described previously (26). The NCT knockdown cell lines were stably transfected with the indicated NCT constructs by using FuGENE (Roche Diagnostics). For NCT expression cells were selected with blasticidin (50 μg/ml).

cDNA Constructs of NCT—For down-regulation of endogenous NCT the pSUPER/NCT-1045 construct was used (26). All NCT constructs expressed in the NCT knockdown cell line contained a cluster of silent mutations conferring RNA interference (RNAi) resistance (26). All cDNA constructs were generated by PCR and sequenced to verify successful mutagenesis.

Antibodies—The polyclonal antibodies αPS1-loop (3027) (27), αAPH-1aL (O2C2) (17), αPEN-2 (1638) (21), αAPP-CT (6657) (28), and αAβ (3926) (29) were described previously. The polyclonal antibody against the N terminus of NCT (αNCT-NT, 1658) was raised against a MBP-NCT (amino acids 320–420) fusion protein, and the C-terminal NCT antibody was obtained from Sigma (N1660). The monoclonal antibodies against Aβ (6E10), the V5 tag, and the penta-His tag were obtained from Senetek and Invitrogen, respectively.

Protein Analysis—Cell lysates were prepared using STEN lysis buffer (1% Nonidet P-40, 50 mM Tris, pH 7.6, 150 mM NaCl, 2 mM EDTA). For co-immunoprecipitations CHAPS lysis buffer was used (2% CHAPS, 20 mM HEPES, pH 7.2, 100 mM KCl, 2 mM EDTA, 2 mM EGTA). Co-immunoprecipitations were carried out as described before (5). For analysis of secreted Aβ, medium was collected after 5 h of incubation and subjected to a combined immunoprecipitation/immunoblotting protocol, using antibody 3926/6E10 (30).

In Vitro γ-Secretase Activity Assay—The assays were carried out as described previously (15, 31). Briefly, CHAPSO cell lysates (2% CHAPSO, 150 mM sodium citrate, pH 6.4) were immunoprecipitated with αV5 antibody or αPS1-loop antibody (3027), the beads were incubated for 14 h with 0.75 μg of purified recombinant APP-C100, C-terminally histidine-tagged (C100-His6) in 20 μl of assay buffer (150 mM sodium citrate, pH 6.4, 0.25% CHAPSO, 0.1 mg/ml bovine serum albumin, 0.5 mg/ml phosphatidylcholine, 10 mM diethiothreitol, protease inhibitor (Roche Diagnostics, as recommended). Aβ and APP intracellular domain (AICD) were detected by Western blot analysis.

RESULTS

To determine whether the cytoplasmic tail or the TMD of NCT plays a critical role for γ-secretase complex assembly and function, we generated the deletion constructs ΔC NCT-V5 (lacking the cytoplasmic domain) and sNCT-V5 (a soluble NCT variant, which lacks the cytoplasmic domain and the TMD). In addition the TMD of wt NCT was also replaced by the TMD of ADAM-10 to create the NCT variant TM10NCT-V5 (Fig. 1A). These constructs as well as wt NCT-V5 were stably transfected into a HEK 293 cell line stably expressing Swedish mutant APP (swAPP) and a pSUPER-based NCT-1045 small interfering RNA (siRNA)-encoding vector, which stably knocks down endogenous NCT expression by RNAi (16, 26). All constructs are RNAi-insensitive. Consistent with our previous results (26) endogenous NCT expression was dramatically decreased by RNAi (Fig. 1B, lane 2). This is accompanied by reduced PS1, APH-1aL, and PEN-2 expression and a significant increase of the βAPP C-terminal fragments (CTFs) followed by reduced Aβ generation (Fig. 1C, lane 2). In cells expressing wt NCT-V5 (26) the biochemical phenotype of the NCT knockdown was rescued (Fig. 1C). The βAPP CTFs were reduced to normal levels and Aβ production was restored demonstrating normal γ-secretase function (Fig. 1C). In total lysates maturation of wt NCT-V5 was observed (Fig. 1B), which is consistent with the functional restoration of γ-secretase activity (16, 19, 24). NCT maturation was also observed in cells expressing the ΔC NCT-V5 variant, although to a slightly lesser extent than wt NCT (Fig. 1B). ΔC NCT-V5 rescued the loss of γ-secretase function caused by the RNAi mediated knockdown of endogenous NCT. Similar to wt NCT, ΔC NCT-V5 rescued PS1, APH-1aL, and PEN-2 expression, reduced APP CTF levels, and restored Aβ generation (Fig. 1C) demonstrating efficient γ-secretase complex assembly and function. In contrast, the NCT variants TM10NCT-V5 and sNCT-V5 entirely failed to mature (Fig. 1B, panel aV5) and to restore expression of PS1 fragments, AHP-1aL and PEN-2 (Fig. 1C). Consequently, they did not reduce APP CTF accumulation and failed to restore Aβ production (Fig. 1C).

Thus the authentic TMD of NCT is apparently necessary for NCT function and γ-secretase complex formation whereas the cytoplasmic tail of NCT is dispensable. To identify a critical region within the NCT TMD required for complex formation, short domains of the NCT TMD were sequentially replaced with that of ADAM-10 (Fig. 2A). Chimeras replacing one-third (TM-NA) or two-thirds (TM-NA) of the C-terminal region of the authentic NCT TMD with the corresponding transmembrane sequences of ADAM-10 were able to mature (Fig. 2B). To further prove if the N-terminal region of the NCT TMD is required for maturation of NCT and γ-secretase complex assembly, three additional chimeras (TM-ANA, TM-ANN, TM-AAN; Fig. 2A) were expressed in the NCT knockdown cell line
expsecretase activity contributed by remaining small amounts of the mature NCT variant TM-ANN were also co-immunoprecipitated (Fig. 2C). In all these cases the mature species of NCT variants were preferentially co-precipitated (Fig. 2C) as expected (16, 18, 19, 24). As discussed above, the NCT variants ΔC, TM-NAa, and TM-NNa showed less co-immunoprecipitation with PS1 as compared with wt NCT (Fig. 2C). These data were supported by co-immunoprecipitation experiments using the α5 antibody to exogenous NCT. The NCT variants wt, ΔC, TM-NAa, TM-NNa, and to a weaker extent TM-ANN co-immunoprecipitated the PS1 C-terminal fragment (Fig. 2D). Again, NCT TM-NAa co-immunoprecipitated the PS1 fragment to a lesser extent than wt NCT (Fig. 2D). Co-immunoprecipitation of APH-1αL occurred with wt NCT, ΔC, TM-NAa, and TM-NNa, confirming assembly into a functional γ-secretase complex (see also Fig. 3). Since TM-ANN is the chimera with the weakest PS interaction, the APH-1αL interaction is apparently below detection limit (Fig. 2D). This is supported by our finding that NCT-ANN does exhibit γ-secretase activity in a highly sensitive in vitro assay (Fig. 3; see below).

To determine whether the NCT chimeras, which restored γ-secretase complex formation allow generation of Aβ and the AICD we performed in vitro γ-secretase activity assays (15, 31). To rule out any γ-secretase activity contributed by remaining small amounts of endogenous complexes, CHAPSO lysates of the indicated cell lines were immunoprecipitated using the α5 antibody. All NCT constructs, which interact with γ-secretase complex components, are functionally active in the in vitro γ-secretase assay. CHAPSO cell lysates were prepared and γ-secretase complexes containing exogenous NCT were selectively immunoprecipitated with α5 antibody. As a control, endogenous γ-secretase was precipitated from CHAPSO lysates of HEK cells expressing swAPP, using the α5 antibody and Western blotting with antibodies 6E10 (upper panel) and α-penta-His (lower panel). Asterisks indicate nonspecific bands.

In A, the sequence of the NCT (gray box) and ADAM-10 TMD (hatched box) chimeras. B, HEK 293 cells expressing swAPP and Nct-1045 siRNA were stably transfected with the indicated siRNA sequences. Cell lysates were analyzed for exogenous NCT expression by Western blot using antibodies 6E10 and co-precipitated NCT was detected by Western blotting with antibodies 6E10 and α-penta-His. Note the difference in the level of maturation of the NCT variants. C, CHAPS lysates were analyzed by immunoprecipitation with the αPS1-loop antibody, and co-precipitated NCT was detected by Western blotting with α5 antibody. D, CHAPS lysates were analyzed by immunoprecipitation with α5 antibody and Western blotting with αPS1-loop, αAHP-1αL antibodies. Asterisks indicate nonspecific bands.

DISCUSSION

Assembly of a proteolytically active γ-secretase complex is essential for Aβ generation (7, 8). Identifying the interacting

Assembly of a proteolytically active γ-secretase complex is essential for Aβ generation (7, 8). Identifying the interacting
domains of the complex components will provide insights into the sequential assembly of the γ-secretase complex and will also signify novel targets for therapeutic intervention. Here we investigate the association of NCT with the γ-secretase complex via a deletion analysis followed by co-immunoprecipitation studies and *in vitro* assays for γ-secretase activity. Based on the finding that down-regulation of PS does not eliminate NCT expression, but rather affects its maturation, causing NCT to remain as a free molecule within the ER, evidence exists that NCT may be the initial scaffold for the assembling process (16, 18, 19, 24). Our findings are consistent with the previous findings suggesting that NCT can only mature and leave the ER upon its incorporation into the γ-secretase complex (16, 18, 19, 24, 25). Assembly of NCT into the γ-secretase complex requires the TMD whereas the cytoplasmic domain is largely dispensable. A sequential deletion analysis then indicated that the N-terminal portion of the NCT TMD is sufficient for this interaction. However, the remaining C-terminal portion of the NCT TM domain also contributes to some extent to γ-secretase complex formation. Therefore the overall structure of the NCT TMD appears to play a critical role for interaction with other complex components. Indeed a helical wheel projection of the wt NCT TMD revealed a hydrophilic patch comprised of Thr-3, Gly-7, Ser-14, and Thr-18 (Fig. 4). Changes within this hydrophilic patch appear to affect the capability of the mutant NCT variants to assemble into the γ-secretase complex. Non-functional TMD mutants such as TM-AAN, TM-ANA, or TM_{A10} contain only one remaining hydrophilic amino acid or lack this patch entirely (Fig. 4). In contrast TM-NNA largely preserves this hydrophilic domain (Fig. 4), and consequently this construct efficiently assembles into the γ-secretase complex. Similarly, TM-NAA and TM-AN N also preserve the hydrophilic patch to some extend and are assembled into a functional γ-secretase complex. Thus the hydrophilic TMD may be involved in the interaction with other γ-secretase complex components. Our data do not exclude the possibility that additional luminal sequences may be involved in the interaction as well. However, these would not be sufficient by themselves since expression of sNCT did not rescue the phenotype caused by the knockdown of endogenous NCT. While this manuscript was in preparation Morais et al. (32) presented evidence by using artificial variants of human and Caenorhabditis elegans NCT suggesting that the TMD of these fusion proteins may be required for the assembly of the γ-secretase complex. Our data are consistent with this finding and extend the evidence of the importance of the TMD by functional assays using authentic NCT proteins. Furthermore, our deletion analysis allowed us to identify the N-terminal third of the NCT TMD as an important interacting domain. In addition we performed our investigations in a NCT knockdown background. In our opinion this is the only way to prove or disprove functional activity of a γ-secretase complex component. Overexpression by itself may not be sufficient. In the case of NCT little or no replacement is observed (13), thus still allowing normal γ-secretase function.

**Fig. 4.** A helical wheel projection containing the 18 N-terminal amino acids of the TMD of wt NCT and the TMD swap constructs, using the following program: cti.itc.virginia.edu/~cmg/Demo/wheel/wheelApp.html. Polar, uncharged amino acids are marked with **bold circles.** + and — reflect the ability of the respective fusion protein to reconstitute a functional γ-secretase complex.
upon overexpression of non-functional NCT. Therefore, the function of mutant NCT variants can only be conclusively analyzed in a NCT knock-out/down background.

Taken together, our data demonstrate that NCT incorporation into the γ-secretase complex occurs predominantly via the N-terminal third of its TMD. In addition the middle part of the TMD facilitates incorporation and maturation. Thus our data suggest that the authentic TMD in its correct folding is required for fully functionally active NCT. This includes the presence of a hydrophile patch. The cytoplasmic tail seems to be largely dispensable for function and may primarily be required to assure appropriate membrane anchoring of NCT.

Previously a pre-complex of APH-1 and NCT has been reported (17, 23, 32–34). Our data suggest that NCT interacts with APH-1 via its TMD, because expression of TM_A10 NCT is not able to rescue APH-1 expression in the NCT knockdown cell line. Moreover APH-1 did not co-precipitate with TM_A10 NCT. Additional work will be required to identify the TMD of APH-1 for support and discussion.

Acknowledgments—we thank Drs. G. Yu and P. St George-Hyslop for the sAPH-1L antibody and the NCT cDNA and Dr. R. Agami for the pSUPER vector. We thank Drs. C. Wild-Bode and S. Lichtenthaler for support and discussion.

REFERENCES
1. Hardy, J., and Selkoe, D. J. (2002) Science 297, 353–356
2. Sisodia, S. S., and St George-Hyslop, P. H. (2002) Nat Rev. Neurosci. 3, 281–290
3. Walsh, D. M., Kryubin, I., Faddeeva, J. V., Cullen, W. K., Anwyll, R., Wolfe, M. S., Rowan, M. J., and Selkoe, D. J. (2002) Nature 416, 535–539
4. Vassar, R., and Citron, M. (2000) Neuron 27, 419–422
5. Capell, A., Grunberg, J., Pesold, B., Diehlmann, A., Citron, M., Nixon, R., Beyreuther, K., Selkoe, D. J., and Haass, C. (1998) J. Biol. Chem. 273, 3205–3211
6. Yu, G., Chen, F., Levesque, G., Nishimura, M., Zhang, D. M., Levesque, L., Rogaeva, E., Xu, D., Liang, Y., Duthie, M., St George-Hyslop, P. H., and Fraser, P. E. (1998) J. Biol. Chem. 273, 16470–16475
7. Haass, C., and Steiner, H. (2002) Trends Cell Biol. 12, 566–562
8. De Strooper, B. (2003) Neuron 38, 9–12
9. Li, Y. M., Lai, M. T., Xu, M., Huang, Q., DiMuzio-Mower, J., Sardana, M. K., Shi, X. P., Yin, K. C., Shafer, J. A., and Gardell, S. J. (2000) Proc Natl Acad Sci U S A 97, 6138–6143
10. Sherrington, R., Rogaeva, E. I., Liang, Y., Rogaeva, E. A., Levesque, G., Ireda, M., Chi, H., Lin, C., Li, G., Holman, K., Touda, T., Mar, L., Foncin, J.-F., Bruni, A. C., Montes, M. P., et al. (1995) Nature 375, 754–760
11. Wolfe, M. S., Xia, W., Ostaszewski, B. L., Diehl, T. S., Kimberly, W. T., and Selke, D. J. (1999) Nature 399, 513–517
12. Francis, R., McGrath, G., Zhang, J., Buddy, D. A., Sym, M., Apfeld, J., Nicoll, M., Maxwell, M., Bai, B., Ellis, M. C., Parks, A. L., Xu, W., Li, J., Gurney, M., Myers, R. L., Hines, C. S., Hieberg, R., Ruble, C., Nye, J. S., and Curtis, W. (2002) Dev Cell 3, 83–93
13. Yu, G., Nishimura, M., Arawaka, S., Leventian, D., Zhang, L., Tandon, A., Song, Y. Q., Rogaeva, E., Chen, F., Kawarai, T., Supala, A., Levesque, L., Yu, H., Yang, D. S., Holmes, E., Milman, P., Liang, Y., Zhang, D. M., Xu, D. H., Sato, C., Rogaeva, E., Smith, M., Janus, C., Zhang, Y., Abersold, R., Farrer, L. S., Sorbi, S., Bruni, A., Fraser, P., and St George-Hyslop, P. (2000) Nature 407, 48–54
14. Goutte, C., Tsunozaki, M., Hale, V. A., and Priss, J. R. (2002) Proc Natl Acad Sci U S A 99, 775–779
15. Edsbaer, D., Winkler, E., Regula, J. T., Pesold, B., Steiner, H., and Haass, C. (2003) Nat Cell Biol 5, 486–488
16. Edsbaer, D., Winkler, E., Haass, C., and Steiner, H. (2002) Proc Natl Acad Sci U S A 99, 8668–8671
17. Gu, Y., Chen, F., Sanje, N., Kawarai, T., Hasegawa, H., Duthie, M., Li, W., Ruan, X., Luthra, A., Mount, H. T., Tandon, A., Fraser, P., and St George-Hyslop, P. (2001) J Biol Chem 276, 7374–7380
18. Kimberly, W. T., LaVee, M. J., Ostaszewski, B. L., Ye, W., Wolfe, M. S., and Selkoe, D. J. (2002) J Biol Chem 277, 35113–35117
19. Leem, J. Y., Vijayan, S., Han, P., Cai, D., Machura, M., Lopes, K. O., Veselits, M. L., Xu, H., and Thranakaran, G. (2002) J Biol Chem 277, 19236–19240
20. Luo, W. J., Wang, H., Li, H., Kim, B. S., Shah, S., Lee, H. E., Thranakaran, G., Kim, T. W., Yu, G., and Xu, H. (2002) J Biol Chem 276, 7850–7854
21. Steiner, H., Winkler, E., Edsbaar, D., Prokop, S., Basset, G., Yamazaki, A., Kostka, M., and Haass, C. (2000) J Biol Chem 275, 39062–39065
22. Yang, D. S., Tandon, A., Chen, F., Yu, G., Yu, H., Arawaka, S., Hasegawa, H., Duthie, M., Schmidt, S. D., Ramabadran, T. V., Nixon, R. A., Mathews, P. M., Gandy, S. E., Mount, H. T., St George-Hyslop, P., and Fraser, P. E. (2002) J Biol Chem 277, 28135–28142
23. Takasugi, N., Tomita, T., Hayashi, I., Tsuruoka, M., Niimura, M., Takahashi, Y., Thranakaran, G., and Iwatsubo, T. (2003) Nature 422, 438–441
24. Herreman, A., Van Gassen, G., Bentahir, M., Nyabi, O., Craessaerts, K., Mueller, U., Annaert, W., and De Strooper, B. (2001) J Cell Sci 116, 1127–1136
25. Kaetzer, C., Lammich, S., Edsbaar, D., Ertl, M., Riedtler, J., Capell, A., Steiner, H., and Haass, C. (2002) J Cell Biol 158, 551–561
26. Shirotani, K., Edsbaer, D., Capell, A., Schmitz, J., Steiner, H., and Haass, C. (2003) J Biol Chem 278, 16474–16477
27. Capell, A., Saffrich, R., Olof, J. C., Meyr, L., Walter, J., Grumberg, J., Mathews, P., Nixon, R., Dotti, C., and Haass, C. (1997) J Neurochem 69, 2432–2440
28. Capell, A., Steiner, H., Rognz, H., Keck, S., Baader, M., Grimm, G. M., Baumester, R., and Haass, C. (1997) J Neurochem 69, 16085–16088
29. Wild-Bode, C., Yamazaki, T., Capell, A., Leimert, U., Steiner, H., Ihara, Y., and Haass, C. (1997) J Biol Chem 272, 16085–16088
30. Sastre, M., Steiner, H., Fuchs, K., Capell, A., Multhaup, G., Condron, M. M., Teplow, D. B., and Haass, C. (2001) EMBO Rep 2, 835–841
31. Esler, W. P., Kimberly, W. T., Ostaszewski, B. L., Ye, W., Diehl, T. S., Selkoe, D. J., and Wolfe, M. S. (2002) Proc Natl Acad Sci U S A 99, 2729–2725
32. Morris, V. A., Crystal, A. S., Pijak, D. S., Carlin, D., Costa, J., Lee, V. M., and Doms, R. W. (2003) J Biol Chem 278, 43284–43291
33. LaVoie, M. J., Fraering, P. C., Ostaszewski, B. L., Ye, W., Kimberly, W. T., Wolfe, M. S., and Selkoe, D. J. (2003) J Biol Chem 278, 37213–37222
34. Hu, Y., and Fortini, M. E. (2003) J Cell Biol 161, 685–690